Pneumonitis in cancer patients receiving anti-PD-1 and radiotherapies: Three case reports

Medicine (United States)

Volumn 96, Issue 1, 2017, Pages

  Lu, Chieh Sheng ^a,b,c   Liu, Jin Hwang ^c  

^a KAOHSIUNG ARMED FORCES GENERAL HOSPITAL   (Taiwan)

^b TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^c TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

Anti programmed cell death protein 1 (PD 1) treatment; Immune escape; Pneumonitis; Programmed death ligand 1 (PD L1); Radiotherapy (RT); Upregulation

Indexed keywords

ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; DACARBAZINE; IPILIMUMAB; IRINOTECAN; NIVOLUMAB; OXALIPLATIN; PEMBROLIZUMAB; PROGRAMMED DEATH 1 RECEPTOR; STEROID; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN;

ADENOCARCINOMA; ADJUVANT THERAPY; ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; ADVANCED CANCER; ADVERSE DRUG REACTION; AGED; AMELANOTIC MELANOMA OF THE FINGER; ANTIBIOTIC THERAPY; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CARCINOMATOSIS; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DISEASE SEVERITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPNEA; HAND TUMOR; HEMOPTYSIS; HUMAN; INVASIVE THYMOMA; JEJUNUM ADENOCARCINOMA; LIVER METASTASIS; LUNG LESION; LUNG METASTASIS; LYMPHADENOPATHY; MALE; MALIGNANT NEOPLASM; METASTATIC LYMPHADENOPATHY; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; PHOTODYNAMIC THERAPY; PNEUMONIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTON THERAPY; RADIOFREQUENCY ABLATION; RECTUM ANTERIOR RESECTION; RESPIRATORY FAILURE; SEGMENTECTOMY; STEROID THERAPY; THORAX RADIOGRAPHY; THYMOMA; TUMOR IMMUNITY; UPREGULATION; WEDGE RESECTION; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; CHEMORADIOTHERAPY; JEJUNUM TUMOR; LUNG NEOPLASMS; MELANOMA, AMELANOTIC; NEOPLASMS; PATHOLOGY; SECONDARY; SKIN TUMOR;

ADENOCARCINOMA; AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; CHEMORADIOTHERAPY; HUMANS; JEJUNAL NEOPLASMS; LUNG NEOPLASMS; MALE; MELANOMA, AMELANOTIC; MIDDLE AGED; NEOPLASMS; PNEUMONIA; PROGRAMMED CELL DEATH 1 RECEPTOR; SKIN NEOPLASMS; THYMOMA; THYMUS NEOPLASMS;

EID: 85013843836     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000005747     Document Type: Article

References (20)

1. Verellen D, De Ridder M, Linthout N, et al. Innovations in image-guided radiotherapy. Nat Rev Cancer 2007;7:949-60.
2. Lee LJ, Harris JR. Innovations in radiation therapy (RT) for breast cancer. Breast 2009;18(suppl 3):S103-11.
3. Kapiteijn E, Marijnen CA, Nagtegaal ID, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 2001;345:638-46.
4. Lee Y, Auh SL, Wang Y, et al. Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. Blood 2009;114:589-95.
5. Lugade AA, Moran JP, Gerber SA, et al. Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigenspecific effector cells that traffic to the tumor. J Immunol 2005;174: 7516-23.
6. Kondo K, Yoshizawa K, Tsuyuguchi M, et al. WHO histologic classification is a prognostic indicator in thymoma. Ann Thorac Surg 2004;77:1183-8.
7. Falkson CB, Bezjak A, Darling G, et al. The management of thymoma: a systematic review and practice guideline. J Thorac Oncol 2009;4:911-9.
8. American Society of Clinical Oncology (ASCO) - Cancer. Net. Thymoma - Stages. Cancer. Net Editorial Board; 2016. Available at http://www.cancer.net/cancer-types/thymoma/stages. Accessed: May, 2016.
9. Sasaki H, Tatematsu T, Shitara M, et al. PD1 gene promoter polymorphism in thymoma and myasthenia gravis. J Immunol Clin Res 2014;2:1011.
10. Apetoh L, Ghiringhelli F, Tesniere A, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 2007;13:1050-9.
11. Gardai SJ, McPhillips KA, Frasch SC, et al. Cell-surface calreticulin initiates clearance of viable or apoptotic cells through trans-activation of LRP on the phagocyte. Cell 2005;123:321-34.
12. Ghiringhelli F, Apetoh L, Tesniere A, et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med 2009;15:1170-8.
13. Ma Y, Adjemian S, Mattarollo SR, et al. Anticancer chemotherapyinduced intratumoral recruitment and differentiation of antigenpresenting cells. Immunity 2013;38:729-41.
14. Honeychurch J, Melis MH, Dovedi SJ, et al. Immunogenic potential of irradiated lymphoma cells is enhanced by adjuvant immunotherapy and modulation of local macrophage populations. Leuk Lymphoma 2013;54:2008-15.
15. Illidge T, Lipowska-Bhalla G, Cheadle E, et al. Radiation therapy induces an adaptive upregulation of PD-L1 on tumor cells which may limit the efficacy of the anti-tumor immune response but can be circumvented by anti-PD-L1. Int J Radiat Oncol Biol Phys 2014;90:S776.
16. Deng L, Liang H, Burnette B, et al. Radiation and anti-PD-L1 antibody combinatorial therapy induces T cell-mediated depletion of myeloidderived suppressor cells and tumor regression. Oncoimmunology 2014; 3:e28499.
17. Sharabi AB, Nirschl CJ, Kochel CM, et al. Stereotactic radiation therapy augments antigen-specific PD-1-mediated antitumor immune responses via cross-presentation of tumor antigen. Cancer Immunol Res 2015;3: 345-55.
18. Zeng J, See AP, Phallen J, et al. Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas. Int J Radiat Oncol Biol Phys 2013;86:343-9.
19. Deng L, Liang H, Burnette B, et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest 2014; 124:687-95.
20. Park SS, Dong H, Liu X, et al. PD-1 restrains radiotherapy-induced abscopal effect. Cancer Immunol Res 2015;3:610-9.